Clinical Efficacy and Tolerability of Monotherapy With ADX10059, a mGluR5 Negative Allosteric Modulator, for Symptom Control in Patients With Gastro-Esophageal Reflux Disease (GERD)

被引：0

|

作者：

Zerbib, Frank

Galmiche, Jean-Paul

Mion, Francois

Keywood, Charlotte

机构：

来源：

GASTROENTEROLOGY | 2010年 / 138卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

W1085

引用

收藏

页码：S648 / S648

页数：1

相关论文

共 22 条

[1] Effect of mGluR5 Negative Allosteric Modulator (NAM) ADX10059, Monotherapy, on Reflux Events and Lower Esophageal Sphincter (LES) Function in Patients With Gastro-Esophageal Reflux Disease (GERD)
des Varannes, Stanislas Bruley
Tutuian, Radu
Roman, Sabine
Zerbib, Frank
Mion, Francois
Tack, Jan F.
Malfertheiner, Peter
Galmiche, Jean-Paul
Keywood, Charlotte
GASTROENTEROLOGY, 2010, 138 (05) : S135 - S135
[2] Efficacy and Tolerability of ADX10059, a Negative Allosteric Modulator of mGluR5, On Gastro-Esophageal Reflux: A pH-Impedance Study in Healthy Subjects
Zerbib, Frank
Keywood, Charlotte
GASTROENTEROLOGY, 2009, 136 (05) : A434 - A435
[3] Efficacy and Tolerability of ADX10059, a mGluR5 Negative Allosteric Modulator, as Add on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux Disease (GERD)
Castell, Donald O.
Zerbib, Frank
des Varannes, Stanislas Bruley
Galmiche, Jean Paul
Vaezi, Michael F.
Keywood, Charlotte
GASTROENTEROLOGY, 2011, 140 (05) : S577 - S577
[4] Effect of mGluR5 Inhibition with ADX10059, On Day and Night Time Reflux and Clinical Symptoms, in Patients With Gastro-Esophageal Reflux Disease (GERD): A Proof of Concept Study
Keywood, Charlotte
Tack, Jan F.
GASTROENTEROLOGY, 2009, 136 (05) : A121 - A122
[5] Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease
Zerbib, F.
des Varannes, S. Bruley
Roman, S.
Tutuian, R.
Galmiche, J. -P.
Mion, F.
Tack, J.
Malfertheiner, P.
Keywood, C.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (08) : 911 - 921
[6] A single-blind, placebo-controlled, proof of concept study of the effect of the mGlur5 negative allosteric modulator, ADX10059, on 24hour esophageal PH and clinical symptoms, in patient's with gastro-esophageal reflux disease (GERD)
Keywood, C.
Wakefield, Mark
NEUROPHARMACOLOGY, 2008, 55 (04) : 604 - 605
[7] ADX10059 a Negative Allosteric Modulator of the Metabotropic Glutamate 5 Receptor (mGlur5) Effectively Controls Chorea and Dystonia in a Primate Model of Levodopa Induced Dyskinesia
Keywood, Charlotte G.
Bezard, Erwan
Girard, Francoise
Mutel, Vincent
NEUROLOGY, 2010, 74 (09) : A393 - A393
[8] ADX10059, a negative allosteric modulator of mGluR5, demonstrates proof of concept for a role in the management of migraine, in a placebo controlled phase2a study.
Keywood, C.
Wakefield, Mark
NEUROPHARMACOLOGY, 2008, 55 (04) : 605 - 605
[9] Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH-impedance study in healthy subjects
Zerbib, F.
Keywood, C.
Strabach, G.
NEUROGASTROENTEROLOGY AND MOTILITY, 2010, 22 (08): : 859 - E231
[10] A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease
Keywood, C.
Wakefield, M.
Tack, J.
GUT, 2009, 58 (09) : 1192 - 1199